Investor Backing & Capital Strength:
Evidence shows a $372M Series D in June 2024 led by a16z with Sanofi participation, one of the larger biotech financings that year. The capital is framed as fuel for acquiring or in-licensing assets and expanding AI capabilities, signaling strong investor confidence.
Strategic Partnerships:
A three‑way collaboration with Sanofi and OpenAI announced in May 2024 to build AI software for drug development highlights high‑profile external alignment. Additional partnered activity, such as the 2025 Sanofi deal for gusacitinib, illustrates the company’s model in practice.
Product Line Growth:
Since 2025 the portfolio expanded via in‑licensing and asset‑centric subsidiaries, including an anti‑CD226 mAb (IMIDomics), a miR‑124 activator (Kenmare Bio), and ex‑China rights to a CNS‑penetrant TYK2 inhibitor from Lynk. A planned Phase 1 start in H1 2026 underscores near‑term pipeline progression.
